Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial
Bruno François(Inserm), Maud Fiancette(Roche (Switzerland)), Gaëtan Plantefève(Centre Hospitalier Victor Dupouy), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Céline Gonzalez(Hôpital Dupuytren), Saad Nseir(Hôpital Avicenne), Karim Asehnoune(Inserm), Ferhat Meziani(Université de Strasbourg), Arnaud Desachy, Paul-André de Lame(Aridis Pharmaceuticals (United States)), Emmanuelle Mercier(Centre Hospitalier Universitaire de Tours)
Cited by 110
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976